🎉 Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. 🎉 🎉 Wishing our readers, advertisers and collaborators a purposeful and prosperous 2026. Thank you for being part of our journey as we continue to inform, inspire and build impact together in the year ahead. 🎉

China

WORK Medical Grants East China Distribution Rights for AI-Automated Blood Cell Morphology Analyzer

The collaboration is expected to accelerate market access and drive large-scale commercialisation of the new product...

Everest Medicines Announces Commercialisation Service Agreement and License Agreement with Hasten

The two agreements are expected to create significant financial and strategic synergies...

China Gold Irradiation Introduces IBA’s sustainable X-ray irradiation technology

The Jianxing centre in East China will be the first CGI centre to install X-ray technology...

Singleron's Matrix NEO Receives Class II Medical Device Approval for Automated Single Cell Analysis

Matrix NEO is the world's first automated single-cell analysis platform to achieve medical device clearance, marking a milestone in bringing single-cell sequencing from research laboratories into clinical practice...

CoolMPS™ Brings a New Dimension to Sequencing

The collaboration enables MGI to leverage Swiss Rockets’ strong R&D capabilities and established presence in Europe and the U.S. to commercialise CoolMPS™...

China Launches Magnetic Resonance Platform for Brain-Computer Interface Research

It enables non-invasive, high-resolution in vivo analysis of the entire brain, significantly improving precision in both space and time...

Fangzhou’s XingJie LLM Completes Key National Filing, Setting Stage for Further AI-Driven Chronic Care Innovations

The successful filing of the XJ LLM represents a milestone in Fangzhou’s AI-enabled chronic disease management ecosystem...

Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management

Through this collaboration, Fangzhou’s AI Health Manager will offer personalised care guidance and monitoring...

HighTide’s HTD1801 Shows Long-Term Benefits for Type 2 Diabetes in Phase III Studies

The 52-week data from these two Phase III clinical trials demonstrate the durability of response and highlight the comprehensive long-term clinical benefits of HTD1801 in patients with T2DM...